<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Emmessar Biotech & Nutrition Ltd has submitted a regulatory disclosure confirming it is NOT classified as a Large Corporate under the SEBI circular dated October 19, 2023. The company's outstanding borrowing as on March 31, 2025 stands at NIL, which is why the Large Corporate funding framework does not apply to it. No credit rating is applicable either, consistent with having no debt obligations. The disclosure has been signed by Priyanka Sharma, Company Secretary and Compliance Officer, and submitted to BSE on April 10, 2025.
This is a routine compliance filing with no material impact on shareholders. The NIL outstanding borrowing indicates the company is effectively debt-free, which may be viewed positively as a low financial risk signal, though it could also reflect limited scale of operations.